Jin Matsuyama

Dr. Jin Matsuyama

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2023 in European Journal of Cancer
Verified
Journal Article
Closed access
HKHisato Kawakami
Hisato Kawakami
Yu SunakawaYu Sunakawa
Yu Sunakawa
EIEisuke Inoue
Eisuke Inoue
RMRyo Matoba
Ryo Matoba
KNKenta Noda
Kenta Noda
MFMasashi Fujii
Masashi Fujii

1 September 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
SYSachiko Yamamoto
Sachiko Yamamoto
HKHisato Kawakami
Hisato Kawakami
TKTakayuki Kii
Takayuki Kii
HHhiroki hara
hiroki hara
RKRyohei Kawabata
Ryohei Kawabata
TSTaroh Satoh
Taroh Satoh

23 September 2025 in eClinicalMedicine
Verified
Journal Article
Open access
KYKazuyoshi Yamamoto
Kazuyoshi Yamamoto
YKYukinori Kurokawa
Yukinori Kurokawa
YMYasuhiro Miyazaki
Yasuhiro Miyazaki
TOTakeshi Omori
Takeshi Omori
YYYoshitomo Yanagimoto
Yoshitomo Yanagimoto
YDYuichiro Doki
Yuichiro Doki
Anamorelin, a ghrelin receptor agonist, has shown efficacy in lung cancer cachexia. We conducted the first randomized controlled trial to evaluate its effects in gastric cancer cachexia. In this multicenter, open-label randomized controlled trial conducted across 10 hospitals in Japan, patients with unresectable or recurrent gastric cancer and cachexia receiving chemotherapy (1st-3rd line) were randomized (1:1) to receive oral anamorelin 100 mg daily for 12 weeks (Group A) or no anamorelin (Group N). Randomization was conducted using a computer-generated sequence, stratified be participating institution and the type of surgical procedure. The primary endpoint was the change in lean body mass (LBM) at 8 weeks. The primary, secondary, and safety analyses were performed in the modified per-protocol population, which included all patients who received at least one dose of the assigned treatment and did not meet major protocol violations. This study is registered with the Japan Registry of Clinical Trials, jRCTs051210108. Between November 17, 2021 and July 4, 2024, a total of 217 patients were recruited. Of these, 14 patients did not meet the eligibility criteria, and 203 patients were subsequently randomised. Ultimately 101 in Group A and 97 in Group N were included in the final analysis. At 8 weeks, the increase in mean LBM was greater in Group A (+0.99 kg; 95% CI +0.34 to +1.64) compared to Group N (+0.14 kg; -0.49 to +0.77), but the between-group difference did not reach statistical significance (P = 0.063). As adverse events potentially related to anamorelin, hyperglycemia was observed in Group A: Grade 1-2 in 4 patients (4%) and Grade 3 in 1 patient (1%). No cases of hyperglycemia were observed in Group N. There were no treatment-related deaths in either group. Although no significant difference was observed between the two groups in the primary endpoint, anamorelin showed a trend toward increased LBM with good tolerability, suggesting potential benefit in gastric cancer cachexia. The randomized multicenter design strengthens the findings, though small sample size and treatment heterogeneity are limitations. These results support further evaluation of anamorelin to improve physical condition in this population with limited treatment options. Ono Pharmaceutical Co., Ltd.

22 July 2022 in Medicine
Verified
Journal Article
Open access
KIKiyotsugu Iede
Kiyotsugu Iede
TYTerumasa Yamada
Terumasa Yamada
MUMasami Ueda
Masami Ueda
YTYujiro Tsuda
Yujiro Tsuda
SNShinsuke Nakashima
Shinsuke Nakashima
STShusei Tominaga
Shusei Tominaga
Although the antitumor effects of antihypertensive drugs for patients with advanced pancreatic cancer (APC) have been investigated, their efficacy remains unclear. Previous studies suggest that hypertensive (HT) patients with APC are significantly older than non-HT patients with APC, and that other major baseline differences in patient characteristics which may affect prognosis exist between HT and non-HT patients. It is also possible that antihypertensive drugs lack antitumor activity. Therefore, we herein retrospectively investigated the baseline differences between HT and non-HT patients with APC. From January 2015 to April 2020, 56 patients with APC received nab-paclitaxel plus gemcitabine as first-line chemotherapy at Higashiosaka City Medical Center (Higashiosaka, Japan). Of these 56 patients, 30 were diagnosed with hypertension (HT group); the remaining 26 did not have hypertension (non-HT group). Differences between the two groups were compared and prognostic factors were evaluated. Patients in the HT group had significantly less sarcopenia, a significantly larger body mass index, were significantly older, and significantly more likely to have a regular doctor and primary site in the body and tail of the pancreas than those in the non-HT group. Although no significant difference was found in the treatment response, patients in the HT group were significantly more likely to move to second-line chemotherapy than those in the non-HT group. Survival curves showed that median overall survival (OS) in the HT group was significantly longer (10.5 months) than in the non-HT group (6.8 months, P = .04). Multivariate analysis did not identify the use of antihypertensive drugs as an independent prognostic factor of OS. We identified key baseline differences in the characteristics of APC patients with and without HT, suggesting that major selection bias could occur when investigating the efficacy of antihypertensive drugs in all populations. Therefore, it is possible that antihypertensive drugs lack antitumor activity. To determine the true efficacy of antihypertensive drugs for APC, HT, and non-HT patients in another population should be investigated, or a prospective, randomized, controlled trial conducted that is stratified by HT or non-HT status.

1 January 2001 in The Japanese Journal of Gastroenterological Surgery
Verified
Journal Article
Open access
YUYoshio Uemura
Yoshio Uemura
KKKenji Kobayashi
Kenji Kobayashi
KYKoji Yoshida
Koji Yoshida
YSYosuke Seki
Yosuke Seki
JMJin Matsuyama
Jin Matsuyama
TKTadashi Kaneko
Tadashi Kaneko

27 January 2022 in Advances in Digestive Medicine
Verified
Journal Article
Open access
PDF file
NSNaoko Sekiguchi
Naoko Sekiguchi
JMJin Matsuyama
Jin Matsuyama
MKMasahiro Koh
Masahiro Koh
KIKiyotsugu Iede
Kiyotsugu Iede
MUMasami Ueda
Masami Ueda
TYTerumasa Yamada
Terumasa Yamada
Patients suffering from appendicitis with severe pathological findings or microperforation have a poor prognosis. Therefore, when selecting treatments, it is critical to clarify the factors related to histopathological severity and the presence of microperforation in cases diagnosed as mild appendicitis. We retrospectively collected data from 357 consecutive patients diagnosed with acute appendicitis based on symptoms such as fever, physical findings, blood tests, and imaging findings who underwent surgery at the Higashiosaka City Medical Center between January 2016 and December 2020. We investigated the predictors of pathological severity and the presence or absence of microperforations. Of the 335 patients, 252 (75%) had clinically mild appendicitis. In the multivariate analysis, diameter of the appendix ≥10.9 mm (P = .0013) and C‐reactive protein ≥5.0 mg/dl (P = .0011) were related to gangrenous appendicitis, with odds ratios of 2.67 (95% confidence interval: 1.23‐5.80) and 3.88 (95% confidence interval: 1.71‐8.77), respectively. On the other hand, the presence of an appendicolith (P = .0083) and duration from onset to surgery ≥2 days (P = .0033) were related to microperforation, with odds ratios of 6.82 (95% confidence interval: 1.64‐28.4) and 3.73 (95% confidence interval: 1.21‐12.4), respectively. Patients with gangrenous appendicitis or microperforation had higher rates of postoperative complications, including more cases of Clavien‐Dindo classification III and longer hospital stays (P < .05). Even in cases of clinically mild appendicitis, there is a possibility of microperforation or gangrenous appendicitis. Therefore, it is essential to carefully select the treatment in cases with more than 2 days after symptom onset, a dilated appendix, and an appendicolith.